GlassScriptPhysician profile
Jeffrey Craven
NPI 1104821206
$406.68
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $83.01 · 2021: $42.18 · 2022: $43.87.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $151.94 | 2019-2020 | |
| Indivior INC. | $89.55 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $60.13 | 2020-2022 | |
| Mdd US Operations, LLC | $45.93 | 2020 | |
| Orexo US, INC. | $45.13 | 2019 | |
| Abbvie INC. | $14.00 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Craven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.